You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME

IBS: Improving Diagnosis, Serotonin Signaling, and Implications for Treatment

  • Authors: Authors: Lucinda Harris, MD; Lin Chang, MD
  • THIS ACTIVITY HAS EXPIRED
Start Activity


Target Audience and Goal Statement

This activity is intended for the physician and other healthcare professionals specializing in the care of the patient with irritable bowel syndrome (IBS).

The goal of this activity is to familiarize the clinician with the clinical relevance of serotonergic signaling in the gut, mechanisms of visceral hypersensitivity, and the role of pathophysiology in understanding symptom presentation in IBS, all with a view toward implications for disease management.

Upon completion of this activity, participants will be able to:

  1. Review issues important to the appropriate diagnostic evaluation of the patient suspected of having IBS.
  2. Explore the relationship between the pathophysiology of IBS and mechanisms of serotonin signaling.
  3. Evaluate the utility/role of serotonergic interventions in the management of patients with IBS.


Author(s)

  • Lin Chang, MD

    Associate Professor of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California; Co-Director, Center for Neurovisceral Sciences & Women's Health at UCLA, Los Angeles, California

    Disclosures

    Disclosure: Dr. Chang disclosed that she has received grants for clinical research from, has served as an advisor or consultant for, and is on the Speakers' Bureau for Novartis and Glaxo SmithKline. She has received grants for clinical research from and has served as an advisor or consultant for Forest Laboratories, Solvay, and AstraZeneca. Dr. Chang reported that she discusses the investigational products cilansetron, prucalopride, renzapride, paroxetine, fluoxetine, venlafaxine, and desipramine.

  • Lucinda A. Harris, MS, MD

    Associate Professor of Clinical Medicine, Weill Medical College of Cornell University; Associate Attending, The New York Presbyterian Hospital, New York, NY

    Disclosures

    Disclosure: Dr. Harris disclosed that she is on the Speakers' Bureau for Novartis , Janssen, GlaxoSmithKline, TAP Pharmaceuticals, and Wyeth. She has received grants for clinical research from Solvay, Forest Laboratories, and Glaxo SmithKline. She has served as an advisor or consultant for Solvay, and GlaxoSmithKline. Dr. Harris reported that she discusses the investigational products cilansetron, prucalopride, renzapride, paroxetine, fluoxetine, venlafaxine, and desipramine.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

The credit that you receive is based on your user profile.

CME

IBS: Improving Diagnosis, Serotonin Signaling, and Implications for Treatment

Authors: Authors: Lucinda Harris, MD; Lin Chang, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

processing....

Introduction

Many patients with irritable bowel syndrome (IBS) have walked into their physician's office and said, "The last doctor told me my symptoms were all in my head." Those physicians may have been right, but not in a way they anticipated.

Over the past 50 years, evolving conceptual mechanisms have been proposed to explain the pathophysiology of IBS. These mechanisms have ranged from a purely psychological disorder to such physiologic conditions as a primary abnormality in gastrointestinal (GI) motility or visceral hypersensitivity. However, recent scientific data have increasingly supported that a dysregulation in brain-gut interactions resulting in alterations in GI motility, secretion, and sensation is the principal pathophysiologic mechanism underlying IBS.[1] Brain-gut interactions are mediated largely by the autonomic nervous system, which is comprised of the parasympathetic (vagal and sacral parasympathetic), sympathetic, and enteric nervous systems (ENS). Many factors (both central and peripheral) may contribute to an altered brain-gut axis, including genetic predisposition, chronic stress, inflammation/infection, and environmental parameters.[1] These alterations may subsequently lead to disturbances in intestinal motility, visceral sensitivity, and mucosal immune response and permeability. In IBS, these disturbances result in symptoms of abdominal pain or discomfort and altered bowel function, the defining characteristics of this disorder.[2]

There are many neurotransmitters and hormones that mediate bidirectional brain-gut communication. Serotonin (5-hydroxytryptamine [5-HT]) is one of the key mediators of gut motility, secretion, and sensation. Most of the serotonin is localized in the GI tract and is found in enterochromaffin (EC) cells and enteric neurons.[3] EC cells sense luminal factors such as food or mechanical distension in the gut, and release serotonin; 5-HT receptors on intrinsic primary afferent neurons (IPANs) as well as extrinsic spinal or vagal afferent neurons are activated. The ENS regulates secretion and peristalsis, whereas vagal and spinal afferents modulate nonpainful and painful sensations, respectively.[4] There are at least 7 main classes of 5-HT receptors. Particularly important for lower gut function and regulation are the 5-HT1P, 5-HT3, and 5-HT4 receptors. These receptors have been the focus of research evaluating the pathophysiologic mechanisms of IBS as well as targets for the development of novel agents in the treatment of functional gastrointestinal disorders. There is also evidence to suggest that other older serotonergic agents -- that is, tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) -- may modulate intestinal function as well.[3] The roles of other neuropeptides and their receptors are also currently being explored as potential molecular targets for drug development.

The development of more effective treatment for IBS is crucial because it is one of the most common disorders seen by gastroenterologists and primary-care physicians, but patients are often not satisfied with traditional therapies. In addition, proper diagnosis and treatment are particularly critical for a number of reasons. Studies have demonstrated the dramatic impact of this disorder on the quality of life of patients with IBS compared with the general population and with individuals with other chronic health conditions.[5,6] In addition, patients with IBS utilize the healthcare system for both GI and non-GI complaints more than patients without IBS.[7] The latter in turn impacts the productivity of patients with IBS such that their absenteeism from work or school has been found to be 3 times higher than that of patients without IBS.[8] Not surprisingly, economic studies have demonstrated that this disorder is costly to the healthcare system and to the economic system as a whole, resulting in an annual associated cost of up to $30 billion.[9,10]

The challenge for clinicians is to identify individuals with IBS despite the fact that no diagnostic biologic marker currently exists for this disorder, and to manage their symptoms despite the lack of effective treatment. Studies evaluating the utility of symptom-based criteria and medical tests in the diagnosis of IBS vs organic GI disorders have resulted in recent recommendations for a more cost-effective diagnostic approach.[11] Although many patients may respond to reassurance, life-style changes, and traditional therapies, it is important for healthcare providers to familiarize themselves with advances in the pathophysiologic mechanisms of IBS that have subsequently led to the development of novel therapeutic agents, such as the serotonergic medications. In addition, these advances have inspired a new look at older medications that affect the serotonin receptors.